scholarly journals Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis

2020 ◽  
Vol 124 ◽  
pp. 1-14 ◽  
Author(s):  
Sufei Wang ◽  
Pei Ma ◽  
Guanzhou Ma ◽  
Zhilei Lv ◽  
Feng Wu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations

2013 ◽  
Vol 8 (3) ◽  
pp. 295-300 ◽  
Author(s):  
Niki Karachaliou ◽  
Carlota Costa ◽  
Ana Gimenez-Capitan ◽  
Miguel Angel Molina-Vila ◽  
Jordi Bertran-Alamillo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mrna Expression ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

2015 ◽  
Vol 16 (6) ◽  
pp. e223-e228 ◽  
Author(s):  
Giovenzio Genestreti ◽  
Marcello Tiseo ◽  
Hirotsugu Kenmotsu ◽  
Wakuda Kazushige ◽  
Monica Di Battista ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Platinum Sensitive

scholarly journals An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0168795 ◽  
Author(s):  
Wen-E Wei ◽  
Nai-Quan Mao ◽  
Shu-Fang Ning ◽  
Ji-Lin Li ◽  
Hai-Zhou Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis

2019 ◽  
Vol 40 (1) ◽  
pp. 427-433 ◽  
Author(s):  
LETIZIA GIANONCELLI ◽  
GIANLUCA SPITALERI ◽  
ANTONIO PASSARO ◽  
DAVIDE RADICE ◽  
CATERINA FUMAGALLI ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Retrospective Analysis ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Comparison and analysis among expression of CRP and tumor markers in advanced non-small cell lung cancer patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17126-17126
Author(s):  
W. Dong ◽  
X. Ren ◽  
P. Liu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Cell Lung Cancer ◽  
Squamous Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Significant Difference

17126 Background: To investigate the correlation of C-reactive protein (CRP) and tumor markers such as carcinoembryonic antigen (CEA), CA125, cytokeratin 19 antibody (Cyfra 21–1) in non-small cell lung cancer (NSCLC) patients. Methods: CRP, CEA, CA125, Cyfra 21–1 were measured in the serum of 79 patients with advanced non-small cell lung cancer (stage III and IV ) by independent samples t test. Results: It showed statistically significant difference (P < 0.05) in the level of CRP, CEA, CA125, Cyfra211 between lung cancer patients (25.21 ± 19.12 mg/L, 62.89 ± 53.96 ng/L, 46.36 ± 30.03 U/L, 6.85 ± 2.42 ng/L, respectively) and the control subjects. CRP, CA125 showed no significant difference between squamous carcinoma and adenocarcinoma (P = 0.832, 0.406, respectively). CEA was higher in adenocarcinoma than in squamous carcinoma (P = 0.002). Cyfra211 was lower in adenocarcinoma than in squamous carcinoma (P = 0.039). The increase of CRP was accompanied with the increase of CEA, CA125 and Cyfra211 (p < 0.05). At the same time, CRP elevated while CEA, CA125, Cyfra211 increased (p < 0.05). Conclusions: All of CRP, CEA, CA125 and Cyfra211 increased in advanced non-small lung cancer. Combined monitoring on CRP with CEA, CA125, Cyfra211 may be a complementary method in advanced non-small cell lung cancer patients. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document